A real-world prospective analysis of the relationship between nanoliposomal irinotecan and fluorouracil with folinic acid and neutropenia in patients with pancreatic cancer (NAPOLEON-2 study, NN-2401).

被引：0
作者：
Shirakawa, Tsuyoshi
Araki, Tomonori
Shimokawa, Mototsugu
Otsuka, Taiga
Nakazawa, Junichi
Shimokawa, Hozumi
Koga, Futa
Oda, Hisanobu
Takeshita, Shigeyuki
Arima, Shiho
Arita, Shuji
Kawaguchi, Yasunori
Nishikawa, Kazuo
Taguchi, Hiroki
Jikuya, Kenichi
Sakai, Tatsunori
Ueda, Yujiro
Sakae, Takahiro
Mizuta, Toshihiko
Mitsugi, Kenji
机构：
[1] Clin Hematol Oncol Treatment Study Grp, Fukuoka, Japan
[2] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki, Japan
[3] Yamaguchi Univ, Grad Sch Med, Dept Biostat, Yamaguchi, Japan
[4] Minato Med Clin, Tokyo, Japan
[5] Kagoshima City Hosp, Kagoshima, Japan
[6] Japan Community Healthcare Org, Kitakyushu, Fukuoka, Japan
[7] Saga Med Ctr Koseikan, Saga, Japan
[8] Saiseikai Kumamoto Hosp, Kumamoto, Japan
[9] Japanese Red Cross Nagasaki Genbaku Hosp, Nagasaki, Japan
[10] Kagoshima Univ, Grad Sch Med & Dent Sci, Kagoshima, Japan
[11] Miyazaki Prefectural Miyazaki Hosp, Miyazaki, Japan
[12] Asakura Med Assoc Hosp, Asakura, Japan
[13] Oita Univ, Fac Med, Yufu, Japan
[14] Imakiire Gen Hosp, Kagoshima, Japan
[15] Natl Hosp Org, Kumamoto, Japan
[16] Japanese Red Cross Kumamoto Hosp, Kumamoto, Japan
[17] Saiseikai Sendai Hosp, Satsumasendai, Japan
[18] Fujikawa Hosp, Saga, Japan
[19] Sasebo Kyosai Hosp, Sasebo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.762
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：762 / 762
页数：1
相关论文
共 27 条
  • [1] Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301)
    Araki, Tomonori
    Sonoda, Yuki
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Hayashi, Kohei
    Honda, Takuya
    Nakao, Kazuhiko
    Shibuki, Taro
    Nakazawa, Junichi
    Arima, Shiho
    Miwa, Keisuke
    Okabe, Yoshinobu
    Koga, Futa
    Ueda, Yujiro
    Kubotsu, Yoshihito
    Shimokawa, Hozumi
    Takeshita, Shigeyuki
    Komori, Azusa
    Nishikawa, Kazuo
    Otsu, Satoshi
    Hosokawa, Ayumu
    Oda, Hisanobu
    Sakai, Tatsunori
    Arita, Shuji
    Kawahira, Machiko
    Taguchi, Hiroki
    Tsuneyoshi, Kengo
    Kawaguchi, Yasunori
    Fujita, Toshihiro
    Sakae, Takahiro
    Shirakawa, Tsuyoshi
    Mizuta, Toshihiko
    Mitsugi, Kenji
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [2] Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
    Koga, F.
    Shirakawa, T.
    Shimokawa, M.
    Otsuka, T.
    Shimokawa, H.
    Nakazawa, J.
    Oda, H.
    Takeshita, S.
    Kawaguchi, Y.
    Arita, S.
    Taguchi, H.
    Sakai, T.
    Nishikawa, K.
    Arima, S.
    Ueda, Y.
    Kawahira, M.
    Sakae, T.
    Ide, Y.
    Mizuta, T.
    Mitsugi, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1534 - S1534
  • [3] Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
    Sonoda, Y.
    Araki, T.
    Shimokawa, M.
    Otsuka, T.
    Shibuki, T.
    Nakazawa, J.
    Arima, S.
    Miwa, K.
    Koga, F.
    Ueda, Y.
    Kubotsu, Y.
    Shimokawa, H.
    Takeshita, S.
    Nishikawa, K.
    Hosokawa, A.
    Oda, H.
    Arita, S.
    Shirakawa, T.
    Mizuta, T.
    Mitsugi, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1546 - S1546
  • [4] A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer
    Kodama, Tomoko
    Imajima, Takashi
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Kawahira, Masahiro
    Nakazawa, Junichi
    Hori, Takeshi
    Shibuki, Taro
    Arima, Shiho
    Ido, Akio
    Miwa, Keisuke
    Okabe, Yoshinobu
    Koga, Futa
    Ueda, Yujiro
    Kubotsu, Yoshihito
    Shimokawa, Hozumi
    Takeshita, Shigeyuki
    Nishikawa, Kazuo
    Komori, Azusa
    Otsu, Satoshi
    Hosokawa, Ayumu
    Sakai, Tatsunori
    Sakai, Kenji
    Oda, Hisanobu
    Kawahira, Machiko
    Arita, Shuji
    Honda, Takuya
    Taguchi, Hiroki
    Tsuneyoshi, Kengo
    Kawaguchi, Yasunori
    Fujita, Toshihiro
    Sakae, Takahiro
    Shirakawa, Tsuyoshi
    Mizuta, Toshihiko
    Mitsugi, Kenji
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [5] Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302)
    Araki, Tomonori
    Hayashi, Kohei
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Sonoda, Yuki
    Honda, Takuya
    Shibuki, Taro
    Nakazawa, Junichi
    Arima, Shiho
    Miwa, Keisuke
    Koga, Futa
    Ueda, Yujiro
    Kubotsu, Yoshihito
    Shimokawa, Hozumi
    Takeshita, Shigeyuki
    Nishikawa, Kazuo
    Komori, Azusa
    Otsu, Satoshi
    Hosokawa, Ayumu
    Sakai, Tatsunori
    Oda, Hisanobu
    Kawahira, Machiko
    Arita, Shuji
    Taguchi, Hiroki
    Tsuneyoshi, Kengo
    Fujita, Toshihiro
    Sakae, Takahiro
    Kawaguchi, Yasunori
    Shirakawa, Tsuyoshi
    Mizuta, Toshihiko
    Mitsugi, Kenji
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [6] Real-world evidence of nanoliposomal irinotecan and fluorouracil with folinic acid in patients with unresectable or recurrent pancreatic cancer: Final results of a multicenter observational study
    Shinohara, Yudai
    Shirakawa, Tsuyoshi
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Shimokawa, Hozumi
    Nakazawa, Junichi
    Koga, Futa
    Oda, Hisanobu
    Takeshita, Shigeyuki
    Arima, Shiho
    Arita, Shuji
    Kawaguchi, Yasunori
    Nishikawa, Kazuo
    Taguchi, Hiroki
    Jikuya, Kenichi
    Sakai, Tatsunori
    Ueda, Yujiro
    Sakae, Takahiro
    Mizuta, Toshihiko
    Mitsugi, Kenji
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 721 - 721
  • [7] Efficacy and safety of nanoliposomal irinotecan plus fluorouracil and folinic acid after irinotecan-based chemotherapy in patients with advanced pancreatic cancer: Results of the retrospective part of the NAPOLEON-2 study.
    Kawaguchi, Yasunori
    Aikawa, Tomomi
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Shibuki, Taro
    Nakazawa, Junichi
    Arima, Shiho
    Miwa, Keisuke
    Koga, Futa
    Ueda, Yujiro
    Kubotsu, Yoshihito
    Shimokawa, Hozumi
    Takeshita, Shigeyuki
    Nishikawa, Kazuo
    Hosokawa, Ayumu
    Oda, Hisanobu
    Sakai, Tatsunori
    Shirakawa, Tsuyoshi
    Mizuta, Toshihiko
    Mitsugi, Kenji
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 705 - 705
  • [8] Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
    Kusano, W.
    Arita, S.
    Shimokawa, M.
    Otsuka, T.
    Shimokawa, H.
    Nakazawa, J.
    Koga, F.
    Oda, H.
    Takeshita, S.
    Kawaguchi, Y.
    Taguchi, H.
    Sakai, T.
    Nishikawa, K.
    Arima, S.
    Ueda, Y.
    Kawahira, M.
    Sakae, T.
    Shirakawa, T.
    Mizuta, T.
    Mitsugi, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1537 - S1537
  • [9] Multicenter observational study of nanoliposomal irinotecan and fluorouracil/leucovorin in patients with unresectable or recurrent pancreatic cancer (NAPOLEON-2): Final retrospective results.
    Imajima, Takashi
    Shirakawa, Tsuyoshi
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Shibuki, Taro
    Nakazawa, Junichi
    Arima, Shiho
    Miwa, Keisuke
    Koga, Futa
    Kubotsu, Yoshihito
    Ueda, Yujiro
    Hosokawa, Ayumu
    Takeshita, Shigeyuki
    Shimokawa, Hozumi
    Komori, Azusa
    Oda, Hisanobu
    Sakai, Tatsunori
    Arita, Shuji
    Mizuta, Toshihiko
    Mitsugi, Kenji
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 706 - 706
  • [10] Final results of multicenter prospective observational study of nano-liposomal irinotecan, fluorouracil and folinic acid in second-line chemotherapy for advanced pancreatic cancer: The NAPOLEON-2
    Toyodome, K.
    Arima, S.
    Shimokawa, M.
    Otsuka, T.
    Nakazawa, J.
    Shimokawa, H.
    Koga, F.
    Oda, H.
    Takeshita, S.
    Kawaguchi, Y.
    Arita, S.
    Nishikawa, K.
    Jikuya, K.
    Sakai, T.
    Sawase, H.
    Ueda, Y.
    Araki, N.
    Shirakawa, T.
    Mizuta, T.
    Mitsugi, K.
    ANNALS OF ONCOLOGY, 2024, 35 : S144 - S144
123